Keensight Capital, a private equity manager, completed an investment in CatSci, an innovation partner for medicines development. Financial terms were not disclosed. “We are delighted that Ross and Simon have chosen Keensight to support CatSci in its next stage of growth. We believe that CatSci has exceptionally strong potential in a large and continuously developing market that is expected to reach c.$75bn by 2030. Their unique positioning and strong expertise in small molecule R&D, as well as their renowned high-quality scientific services and workforce, make them a critical player in the CRO ecosystem. Keensight is proud to partner with CatSci’s top class management team in their ambitions,” James Mitchell, Keensight Capital Partner.